Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $58.02 -0.58%
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's capital-raising plans expose a major weakness in the AI boom
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
